Outgrowing Legacy Methods: mRNA's Transition from Protein Paradigms
Source: Advancing RNA
AbbVie’s Elaine Peters, Sanofi’s Philippe Talaga, and Tessera’s Ilya Shestopalov highlight the technical limitations of legacy analytical methods in evaluating and measuring mRNA-LNP concentration, structure, purity, integrity, and impurities.
access the Video!
Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue.
X
Enter your credentials below to log in. Not yet a member of Advancing RNA? Subscribe today.
Subscribe to Advancing RNA
X
Subscribe to Advancing RNA